摘要
目的 探讨冠心病应用成纤维细胞生产长因子治疗现状。方法 本次选取80例冠心病患者,均为我院2013年5月~2014年5月收治,随机分组,就常规治疗（对照组,n=40）与联用成纤维细胞生长因子治疗（观察组,n=40）效果展开对比。结果 观察组选取病例总有效率为97.5%,明显高于对照组80.0%（P〈0.05）。两组心功能CRP、LVPW、LVESD、LVEDD治疗前无明显差异（P〉0.05）,疗后均改善,但观察组改善幅度明显优于对照组（P〈0.05）。结论 冠心病采用成纤维细胞生长因子治疗,可显著提高预后,改善心功能,为临床治疗开辟了新的途径,使患者生存质量得到明显改善,对保障生命安全具有非常重要的意义。
Objective To investigate the research status of fiber cell growth factor in the treatment of coronary heart disease. Methods 80 cases with coronary heart disease patients in our hospital from May 2013 to May 2014 were selected, random allocation, the effect with usual care （control group, n=40） and in combination with fibroblast growth factor treatment （observation group, n=40） were compared. Results The total effective rate of selected patients was 97.5%, significantly higher than 80.0% （P 〈 0.05）. Two heart function CRP, LVPW, LVESD, LVEDD treatment had no significant difference （P 〉0.05） before, were improved after treatment, but the magnitude of the improvement in the observation group was better than that in the control group （P 〈 0.05）. Conclusion Coronary heart disease using fibroblast growth factor therapy, can significantly improve the prognosis, improve heart function, for the clinical treatment has opened up new ways to make significant improvement in the quality of life of patients, to ensure the safety of very important significance.
出处
《中国医药科学》
2015年第12期125-126,165,共3页
China Medicine And Pharmacy
关键词
成纤细胞生长因子
冠心病
研究现状
Fibroblast growth factor
CorOnary heart disease
Research status
